In a recent speculative study in T2D individuals, the clinical efficacy of liraglutide, a GLP-1 receptor agonist, was related to the baseline plasma triglycerides and C-peptide levels (79), emphasizing the importance of lipid control. Here, GLP1R is linked to type 2 diabetes mellitus.